NCT02148744View on ClinicalTrials.gov

Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

September 21, 2015

Study Completion Date

September 21, 2015

Conditions

Allergic RhinitisAllergic ConjunctivitisAtopic Dermatitis

Interventions

BIOLOGICAL

XmAb7195

Part 1 and 2: Single IV infusion of XmAb7195 or placebo Part 3: Two-dose sequential IV infusion of XmAb7195 or placebo on Day 1 and Day 8

BIOLOGICAL

Placebo

Trial Locations (1)

21225

Parexel Baltimore Early Phase Clinical Unit, Baltimore

All Listed Sponsors

lead

Xencor, Inc.

INDUSTRY

NCT02148744 - Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis | Biotech Hunter | Biotech Hunter